Pharmaceutical composition of dsRNA and saikosaponin and application thereof

A technology of saikosaponin and bupleurum, which is applied in the drug combination of dsRNA and saikosaponin and its application field, which can solve the problems of no compatibility of active substances, lack of suitable conditions for double-strand pairing, systematic research on factors affecting stability, low fever And other issues

Inactive Publication Date: 2012-05-23
青岛汉河动植物药业有限公司
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, although there are domestic production of oligoinosinic acid and oligocytidylic acid raw materials, there is still a lack of systematic research on the suitable conditions for double-strand pairing and factors affecting stability, and there is no compatibility with other active substances. Aspects of reports
[0005] Pharmacological and toxicological studies at home and abroad have shown that after PIC is applied to animals, transient hypothermia side effects may occur, but how to prevent this side effect has not yet been reported

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition of dsRNA and saikosaponin and application thereof
  • Pharmaceutical composition of dsRNA and saikosaponin and application thereof
  • Pharmaceutical composition of dsRNA and saikosaponin and application thereof

Examples

Experimental program
Comparison scheme
Effect test

specific Embodiment approach 1

[0016] Embodiment 1: This embodiment adopts the following technical scheme: its formula consists of: polykinocytes, saikosaponin and Bupleurum volatile oil; its preparation method is: adding appropriate pharmaceutical excipients to the above components by a certain amount The process is made into a compound preparation; these components have certain synergistic and synergistic effects, and can avoid the side effects of dsRNA.

specific Embodiment approach 2

[0017] Specific implementation mode two: refer to figure 1 , The specific embodiment adopts the following technical scheme: take two groups of test rabbits, inject the simple polyinocide injection and the combined medicine respectively to carry out the pyrogen test, and record the temperature changes of the test rabbits. The results showed that the combined drug could alleviate the pyrogen reaction of poly-inosin injection alone.

specific Embodiment approach 3

[0018] Specific implementation mode three: refer to figure 2 with image 3 , This specific embodiment adopts the following technical scheme: the medicine is diluted to 50 μg / ml with water for injection. 240 test chicks were randomly divided into 6 test groups, 40 in each group. Group I: blank control group; Group II: drug control group (astragalus polysaccharide injection, 20 mg per kilogram of body weight); Group III: vaccine control group (no drug); Group IV: high-dose drug test group (0.1 mg per kilogram of body weight). mg); V group: middle dose drug test group (0.05 mg per kg body weight); VI group: low dose drug test group (0.01 mg per kg body weight). The above chicks were reared in isolated cages, and the blank control group, the positive control group and the medication test group were raised in different chicken houses, and the feeding conditions were kept consistent. After feeding for 10 days, four groups III, IV, V and VI were immunized with Newcastle disease v...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a pharmaceutical composition of dsRNA and saikosaponin and application thereof, in particular to the pharmaceutical composition applied to viral infection prevention and treatment of cultured animals, a preparation method and stability control method thereof. The pharmaceutical composition comprises the following ingredients: 20-50mu g / ml of saikosaponin, bupleurum oil with the content range of ultraviolet absorption value of above 0.45; and 1-3mg / ml of polyinosinic polycytidylic acid with the molecular weight range of 200-500bp (agarose gel electrophoresis method). The preparation method of the pharmaceutical composition comprises the steps of adding proper pharmaceutic adjuvant into the ingredients, matching liquid, filtering, filling and encapsulating, and sterilizing according to water injection production technology, and obtaining the pharmaceutical composition after being checked to be qualified. The pharmaceutical composition can induce animal organism to generate endogenous interferon, thus avoiding virus breeding in the animal bodies.

Description

Technical field: [0001] The invention relates to a medicine used in the prevention and treatment of viral infection of farmed animals and a preparation and stability control method of the combined medicine, in particular to a medicine of dsRNA and saikosaponin and its application. Background technique: [0002] Viral infection is an important factor that causes the death of farmed animals and affects the economic benefits of animal breeding. With the standardization of national veterinary drug quality standards, a large number of antiviral drugs with original local standards have been cancelled. Demand contradictions are becoming increasingly prominent. [0003] In 1967, Field et al. of Merck Pharmaceutical Company in the United States discovered that enzymatically synthesized double-stranded nucleic acid (double strained RNA, dsRNA) has the ability to induce interferon, wherein the induction of polyinosinic-polycytidylic acid (PIC) It has the strongest ability, it can stim...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/713A61K31/7048A61K31/704A61K36/233A61P31/12A61K125/00
Inventor 刘宗柱尹立杰段坤刘西锋
Owner 青岛汉河动植物药业有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap